Precigen (PGEN) Other financing activities (2012 - 2026)
Precigen (PGEN) posted quarterly Other financing activities of $255000.0 for Q1 2026, up 70.0% year-over-year from $150000.0 in Q1 2025, and up 82.14% quarter-over-quarter from $140000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Other financing activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Other financing activities for 12 consecutive years, with $255000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 70.0% year-over-year to $255000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 163.51% YoY), while the FY2025 annual figure was $1.2 million, up 247.4% from the prior year.
- Other financing activities grew to $255000.0 in Q1 2026 per PGEN's latest filing, from $140000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $839000.0 in Q3 2025 and bottomed at $1000.0 in Q1 2022.
- Historically, Other financing activities has averaged $225500.0 across 4 years, with a median of $145000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other financing activities plunged 99.1% — and 2025, when it surged 185.37%.
- Precigen's Other financing activities stood at $1000.0 in 2022, then soared by 29300.0% to $294000.0 in 2024, then sank by 52.38% to $140000.0 in 2025, then soared by 82.14% to $255000.0 in 2026.
- Business Quant data shows PGEN's Other financing activities at $255000.0 in Q1 2026, $140000.0 in Q4 2025, and $839000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Mn |
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 140,000.00 |
| Sep 30, 2025 | 839,000.00 |
| Jun 30, 2025 | 73,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Sep 30, 2024 | 294,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 351,000.00 |
| Jun 30, 2021 | 141,000.00 |
| Mar 31, 2021 | 111,000.00 |
| Dec 31, 2020 | 34.93 Mn |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 66,000.00 |
| Dec 31, 2017 | 12.82 Mn |
| Sep 30, 2017 | 189,000.00 |
| Jun 30, 2017 | 503,000.00 |
| Mar 31, 2017 | 175,000.00 |
| Dec 31, 2016 | -16.60 Mn |